Inflammation

Dupilumab, with or without topical corticosteroids, significantly reduced pain and discomfort in patients with moderate to severe atopic dermatitis.

Treatment targets include several interleukins, immunoglobulin E, and alarmins, pointed out Nicola Hanania, MD, MS, pulmonary critical care physician and director, Airway Clinical Research Center, Baylor College of Medicine, Houston.

Overuse of reliever inhalers among adult patients with asthma is prevalent, but does not necessarily translate into higher all-cause health care utilization (HCU), according to a study published in Scientific Reports.

Categorizing by eosinophilic/noneosinophilic subtype enables better targeted treatment, noted Anne Reihman, MD, third-year pulmonary and critical care fellow, University of Colorado, Division of Pulmonary Sciences and Critical Care Medicine.

Vitamin D used as an adjuvant therapy in children with severe atopic dermatitis may improve clinical outcomes, according to a recent study.

Despite the price, adherence to biologics for asthma is usually good because of the effectiveness, said J. Allen Meadows, MD, president of the American College of Allergy, Asthma & Immunology.

When the first biologic to treat asthma was approved by the FDA in 2003, it needed to be administered subcutaneously in the physician’s office. Now, there are 3 options available for at-home use: mepolizumab, benralizumab, and dupilumab.

There are clear differences between the biologics approved to treat asthma, and finding the right one for a patient requires shared decision-making conversations, said J. Allen Meadows, MD.

Atopic dermatitis (AD) has a negative impact on quality of life, and the burden of this disease in adolescents and their parents should be taken into account as part of the management of AD.

Patients with severe asthma are good candidates for biologics, but choosing which biologic requires a shared decision-making conversation, said J. Allen Meadows, MD, president of the American College of Allergy, Asthma & Immunology.

Improvements in lung function occurred as early as 2 weeks after the first dose of treatment.

New data on the long-term efficacy and safety of dupilumab are very reassuring to patients with asthma, explained J. Allen Meadows, MD, president of the American College of Allergy, Asthma & Immunology.

Patients with type 2-high asthma who were being treated with high-dose inhaled corticosteroids (ICS) had reduced exacerbations and improved lung function when they were switched to dupilumab.

The majority of patients with asthma have type 2 inflammation, and the introduction of dupilumab has changed the treatment space for these patients, said Neal Jain, MD, FAAP, FAAAAI.

In the real world, dupilumab has been as effective as the results in clinical trials, and patients are seeing low exacerbation rates, emergency department visits, and hospitalizations, explained Neal Jain, MD, FAAP, FAAAAI.

Following the onset of the coronavirus disease 2019 (COVID-19) pandemic, changes in pediatric asthma health care delivery patterns resulted in reduced hospital admissions and systemic steroid prescriptions in Philadelphia.

The 2-year study will investigate how devices like the Apple Watch and the iPhone can help patients with asthma better manage their condition.

Patients who have oral corticosteroid–dependent asthma are recommended to use dupilumab, which reduces the use of oral steroids, explained Neal Jain, MD, FAAP, FAAAAI, of Arizona Allergy & Immunology Research.

The high rate of persistence found in the real-world study indicates dupilumab was well tolerated and patients were satisfied with its effectiveness.

The broadest real-life study of dupilumab in atopic dermatitis (AD) found significant improvements in adults with moderate to severe AD that were even greater than the results reported in clinical trials.

Even though dupilumab was a late entrant to the market to treat asthma, its efficacy “speaks for itself,” said Neal Jain MD, FAAP, FAAAAI, of Arizona Allergy & Immunology Research, Arcadia Allergy & Asthma, and San Tan Allergy & Asthma.

Findings from a new study in JAMA do not support the use of vitamin D3 supplementation to prevent severe asthma exacerbations in children with persistent asthma.

Inflammatory skin diseases are often diagnosed by "first impression" and can be easily misdiagnosed. A new smartphone app using artificial intelligence (AI) may be able to assist with the diagnosis of psoriasis, atopic dermatitis, and eczema.

Acute stress was found to be a possible trigger following the loss of a partner, but not a factor in long-term risk for either disorder.

The aim of this study was to assess cytokine levels in patients with refractory chronic rhinosinusitis with nasal polyps and to identify inflammatory markers associated with certain subtypes.